Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification

Abstract Background Hepatitis C virus (HCV) is currently classified into 8 genotypes and 86 subtypes. The objective of this study was to characterize novel HCV subtypes and to investigate the impact of subtypes on treatment outcome. Methods Full-genome sequencing was performed on HCV plasma samples with <85% sequence homology of NS3, NS5A, and/or NS5B to HCV genotype (GT) 1–8 reference strains. Results A total of 14 653 patients with GT1–6 HCV infection were enrolled in clinical studies of sofosbuvir-based regimens. For the majority of the patients, a specific subtype could be assigned based on a close genetic relationship to previously described subtypes. However, for 19 patients, novel subtypes were identified with <85% homology compared with previously described subtypes. These novel subtypes had the following genotypes: 9 in GT2, 5 in GT4, 2 in GT6, and 1 each in GT1, GT3, and GT5. Despite the presence of polymorphisms at resistance-associated substitution positions, 18 of the 19 patients treated with sofosbuvir-containing therapy achieved SVR12. Conclusions Nineteen novel HCV subtypes were identified, suggesting an even greater genetic diversity of HCV subtypes than previously recognized.

[1]  H. Mo,et al.  Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes , 2018, The Journal of infectious diseases.

[2]  T. Asselah,et al.  Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. , 2017, Journal of hepatology.

[3]  M. Manns,et al.  Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.

[4]  T. Asselah,et al.  Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection , 2016, Hepatology.

[5]  N. Izumi,et al.  Resistance Analyses of Japanese Hepatitis C‐Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies , 2016, Journal of Viral Hepatitis.

[6]  E. Svarovskaia,et al.  Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir , 2016, Hepatology.

[7]  A. Bane,et al.  COMMON GENOTYPES AND TREATMENT OUTCOMES OF HCV INFECTION AMONG ETHIOPIAN PATIENTS: A PROSPECTIVE STUDY. , 2016, Ethiopian medical journal.

[8]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[9]  Michael D. Miller,et al.  Genotype- and Subtype-Independent Full-Genome Sequencing Assay for Hepatitis C Virus , 2015, Journal of Clinical Microbiology.

[10]  A. Flaxman,et al.  Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.

[11]  Riina Salupere,et al.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.

[12]  C. Rice,et al.  Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.

[13]  Xiaohong Liu,et al.  The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function , 2012, PloS one.

[14]  M. Otto,et al.  Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus , 2012, Antimicrobial Agents and Chemotherapy.

[15]  M. Otto,et al.  Hepatitis C Virus Nucleotide Inhibitors PSI-352938 and PSI-353661 Exhibit a Novel Mechanism of Resistance Requiring Multiple Mutations within Replicon RNA , 2011, Journal of Virology.

[16]  William A. Lee,et al.  Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase , 2011, Antimicrobial Agents and Chemotherapy.

[17]  M. Manns,et al.  Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. , 2011, Journal of hepatology.

[18]  M. Manns,et al.  126 A PHASE-2B TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF A CASPASE INHIBITOR GS-9450, IN ADULTS FAILING PEG/RBV THERAPY FOR CHRONIC HCV INFECTION , 2011 .

[19]  Huiling Yang,et al.  Novel Hepatitis C Virus Reporter Replicon Cell Lines Enable Efficient Antiviral Screening against Genotype 1a , 2010, Antimicrobial Agents and Chemotherapy.

[20]  M. Otto,et al.  PSI-7851, a Pronucleotide of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication , 2010, Antimicrobial Agents and Chemotherapy.

[21]  O. Gascuel,et al.  New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. , 2010, Systematic biology.

[22]  R. De Francesco,et al.  Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. , 2007, Advanced drug delivery reviews.

[23]  O. Gascuel,et al.  Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative. , 2006, Systematic biology.

[24]  Derrick J. Zwickl.  Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion , 2006 .

[25]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.